{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:38:39Z","timestamp":1789141119847,"version":"build-2803163510"},"reference-count":48,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.bbmt.2019.03.027","type":"journal-article","created":{"date-parts":[[2019,4,2]],"date-time":"2019-04-02T22:02:20Z","timestamp":1554242540000},"page":"1293-1303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms"],"prefix":"10.1016","volume":"25","author":[{"given":"Rupa","family":"Narayan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Tate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan J.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Lowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ginna","family":"Laport","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Negrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Everett H.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2019.03.027_bib0001","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1182\/blood-2009-03-211441","article-title":"TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors","volume":"114","author":"Kohrt","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0002","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.bbmt.2014.02.023","article-title":"Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms","volume":"20","author":"Benjamin","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0003","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa050642","article-title":"Protective conditioning for acute graft-versus-host disease","volume":"353","author":"Lowsky","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0004","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1182\/blood.V94.9.3234","article-title":"Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses","volume":"94","author":"Childs","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0005","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1182\/blood-2004-04-1506","article-title":"Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"104","author":"Baron","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0006","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J Exp Med"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0007","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.4049\/jimmunol.153.4.1687","article-title":"A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency","volume":"153","author":"Lu","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0008","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.bbmt.2011.05.012","article-title":"Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation","volume":"17","author":"Laport","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0009","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/0008-8749(91)90369-M","article-title":"Comparative studies of CD3- and CD3+ CD56+ cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression","volume":"136","author":"Ortaldo","year":"1991","journal-title":"Cell Immunol"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0010","doi-asserted-by":"crossref","first-page":"5944","DOI":"10.1038\/onc.2008.272","article-title":"NKG2D ligands in tumor immunity","volume":"27","author":"Nausch","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0011","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","article-title":"NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy","volume":"28","author":"Guerra","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0012","doi-asserted-by":"crossref","first-page":"E358","DOI":"10.3390\/ijms19020358","article-title":"Innovative clinical perspectives for CIK cells in cancer patients","volume":"19","author":"Introna","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0013","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0014","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/bmt.2011.202","article-title":"The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies","volume":"47","author":"Linn","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0015","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/j.bbmt.2017.07.005","article-title":"Phase II study of sequential infusion of donor lymphocyte infusion and cytokine-induced killer cells for patients relapsed after allogeneic hematopoietic stem cell transplantation","volume":"23","author":"Introna","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0016","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1097\/00007890-200205150-00005","article-title":"Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation","volume":"73","author":"Millan","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0017","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0018","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0019","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0020","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1200\/JCO.2008.16.0259","article-title":"Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype","volume":"26","author":"Breems","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0021","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","article-title":"New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge","volume":"30","author":"Schanz","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0022","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0023","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0024","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0025","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0026","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and Staging Working Group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0027","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.bbmt.2015.08.024","article-title":"Hematopoietic cell transplantation outcomes in monosomal karyotype myeloid malignancies","volume":"22","author":"Pasquini","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0028","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1182\/blood-2013-04-496778","article-title":"Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS)","volume":"122","author":"Saber","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0029","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbmt.2014.11.675","volume":"21","author":"Robin","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0030","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.V86.9.3493.bloodjournal8693493","article-title":"Two pathways of exocytosis of cytoplasmic granule contents and target cell killing by cytokine-induced CD3+ CD56+ killer cells","volume":"86","author":"Mehta","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0031","doi-asserted-by":"crossref","first-page":"43604","DOI":"10.18632\/oncotarget.9871","article-title":"Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0032","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1097\/CJI.0000000000000001","article-title":"IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+ cells and downregulating regulatory T cells as well as IL-35","volume":"36","author":"Tao","year":"2013","journal-title":"J Immunother"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0033","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1089\/hum.2016.092","article-title":"Acute myeloid leukemia targeting by chimeric antigen receptor T cells: bridging the gap from preclinical modeling to human studies","volume":"28","author":"Rotiroti","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0034","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/bjh.12282","article-title":"Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor","volume":"161","author":"Tettamanti","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0035","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaut.2017.08.003","article-title":"Redirecting T cells with chimeric antigen receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia","volume":"85","author":"Biondi","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0036","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1126\/science.1121411","article-title":"Synergistic antitumor effects of immune cell-viral biotherapy","volume":"311","author":"Thorne","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0037","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2013-12-542720","article-title":"Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R","volume":"123","author":"Della Porta","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0038","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/bmt.2016.303","article-title":"MDS disease characteristics, not donor source, predict hematopoietic stem cell transplant outcomes","volume":"52","author":"Pourhassan","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0039","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/leu.2012.297","article-title":"Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia","volume":"27","author":"van Gelder","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0040","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3324\/haematol.2014.116715","volume":"100","author":"Koenecke","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0041","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/sj.leu.2403640","article-title":"Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome","volume":"19","author":"Nakai","year":"2005","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0042","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.bbmt.2004.10.001","article-title":"Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome","volume":"11","author":"Scott","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0043","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.3324\/haematol.2009.019182","article-title":"Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European intergroup trial","volume":"95","author":"de Witte","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0044","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3324\/haematol.2014.106880","volume":"99","author":"Onida","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0045","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbmt.2012.01.009","article-title":"Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS","volume":"18","author":"Gerds","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0046","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1200\/JCO.2012.44.3499","article-title":"Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie-Cellulaire and the Groupe-Francophone des My\u00e9lodysplasies","volume":"30","author":"Damaj","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0047","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2019.03.027_bib0048","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bbmt.2016.10.016","article-title":"Factors determining responses to azacitidine in patients with myelodysplastic syndromes and acute myeloid leukemia with early post-transplantation relapse: a prospective trial","volume":"23","author":"Woo","year":"2017","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119302113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879119302113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:08:08Z","timestamp":1761059288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879119302113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S1083879119302113"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.03.027","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2019.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}